Targeted Protein Degradation Market

Targeted Protein Degradation Market (3rd Edition): Industry Trends and Global Forecasts, till 2035: Distribution by Type of Degrader (SERD, PROTAC and Molecular Glue), Target Indication (Breast Cancer and Multiple Myeloma), Key Geographical Regions (North America (US and Canada), Europe (UK, Germany, France, Italy and Spain), Asia-Pacific (China, South Korea, Japan, India and Australia), and Rest of the World (Brazil and Israel)) and Sales Forecast

  • Lowest Price Guaranteed From USD 4,799

  • Pages
    450

  • View Count
    38102

Targeted Protein Degradation Market Overview

The targeted protein degradation market size is likely to be worth USD 0.48 billion in 2024, and is projected to reach worth USD 6.94 billion by 2035, growing at an annualized rate (CAGR) of 32% during the forecast period 2024-2035. The new research study consists of industry trends, detailed market analysis, grants analysis, patent analysis, publication analysis, clinical trial analysis, market impact analysis, partnerships and collaborations, and funding and investments analysis. In addition, we have provided targeted protein degradation market forecast along with sales forecast of drugs which are being evaluated in later stages of clinical development.

Targeted Protein Degradation Market by Type of Degrader, 2024-2035 (USD Billion)

To learn more about this report, request a free sample copy

Driven by the availability of innovative technology platforms, lucrative partnership, funding and encouraging clinical trial results, along with continuous research and development efforts, the market is poised to grow in the long-run, as several product candidates are expected to receive marketing approval in the coming decade.

Over the years, conventional drug discovery approaches, such as small molecule inhibitors, focused on inhibiting the activity of particular protein to relieve disease symptoms, have faced several challenges. These inhibitors were unable to bind to several potential targets due to their intracellular location and absence of suitable binding pockets. In fact, the existing inhibitors were able to bind to even less than 20% of all disease-causing proteins, leaving 80% of them as undruggable targets. However, with increasing understanding of cellular mechanisms and proteomics, researchers have developed an unconventional approach; targeted protein degraders go beyond inhibition and serve as a promising alternative in the quest for more effective therapies. 

Targeted protein degradation is a novel drug discovery approach that leads to elimination of disease-causing proteins by harnessing cellular machinery within the small molecules. In addition, the modalities responsible for breakdown of proteins are known as targeted protein degraders. Protein degraders are bifunctional small molecules that recruit E3 ubiquitin ligases to the protein of interest and mediate its ubiquitination and subsequent proteolysis by the proteasome, thereby resulting in degradation of a specific protein. In other words, protein degraders regulate biological pathways by selectively downregulating a target protein by degrading them. This process has been shown to be robust, more sensitive and can regulate cellular functions in an effective manner, since it is independent of any attachment with other sites.

Further, in recent years, targeted protein degraders have emerged as a popular therapeutic modality due to the various advantages offered by them, including specificity, stability and minimal off-side effects. Additionally, it is worth noting that these degraders offer broad applicability and can gain selectivity for their protein targets by optimizing the linker length and stabilizing the ternary complexes.

Owing to these advantages, there are several types of degraders that are currently being evaluated under different stages of pre-clinical and clinical development, including Proteolysis-targeting Chimeras (PROTACs), Selective Estrogen Receptor Degraders (SERDs), Selective Androgen Receptor Degraders (SARDs), Endosome-targeting Chimeras (ENDTACs), Photochemically-targeting Chimeras (PHOTACs), Lysosome-targeting Chimeras (LYTACs), DUB (Deubiquitinase) inhibitors, hydrophobic tags, Immunomodulatory Imide Drugs (IMiDs), molecular glues, Selective Hormone Receptor Degraders (SHRDS) and others, for various diseases, especially cancer. Cancer is one of the leading causes of deaths worldwide. In fact, around 10 million cancer related deaths were reported in 2023.  Moreover, it is estimated that, by the end of 2050, over 35 million new cases will be added to the global cancer burden, exerting tremendous physical, emotional and financial strain on the affected individuals, their families, communities as well as the national health systems.

Therefore, several start-ups and big pharma players have entered the targeted protein degradation market, offering novel targeted protein degradation technologies leading to the development of more potent, pharmacologically different and target-specific degraders. Driven by the growing demand for selective and efficacious treatments, the targeted protein degradation market is poised to witness substantial growth during the forecast period.

Targeted Protein Degradation Market Share Insights

The market report presents an in-depth analysis of various targeted protein degradation developers and technology providers in this domain, across different segments, as defined in the below table:

Targeted Protein Degradation Market: Report Attribute / Market Segmentations

Key Report Attributes Details
Base Year 2023
Forecast Period 2024-2035
Market Size 2035 $6.94 Billion
CAGR 32%
Target Indication
  • Breast Cancer
  • Multiple Myeloma
Type of Degrader
  • SERD
  • PROTAC
  • Molecular Glue
Key Geographical Regions
  • North America (US and Canada)
  • Europe (UK, Germany, France, Italy and Spain)
  • Asia-Pacific (China, South Korea, Japan, India and Australia)
  • Rest of the World (Brazil and Israel)
Key Targeted Protein
Degradation Companies
Profiled
  • Arvinas
  • AstraZeneca
  • BeiGene
  • Bristol-Myers Squibb
  • C4 Therapeutics
  • Eisai Therapeutics
  • InnoCare Pharma
  • Kangpu Biopharmaceuticals
  • Kintor Pharmaceutical
  • Loxo Oncology
  • Medivir
  • Monte Rosa Therapeutics
  • Olema Oncology
  • Radius Health
  • Ranok Therapeutics
  • Roche
  • Sanofi
  • Zentalis Pharmaceuticals 

(Full list of 115+ targeted protein degradation companies captured in the market landscape analysis of the report) 

PowerPoint Presentation
(Complimentary)
Available
Customization Scope 15% Free Customization
Excel Data Packs
(Complimentary)
  • Market Landscape - Targeted Protein Degradation Therapies
  • Market Landscape - Targeted Protein Degradation Technologies
  • Clinical Trial Analysis
  • Grants Analysis
  • Funding and Investments Analysis
  • Partnerships and Collaborations 
  • Patent Analysis
  • Publication Analysis
  • Market Forecast and Opportunity Analysis - Targeted Protein Degradation Therapies
  • Market Forecast and Opportunity Analysis - Targeted Protein Degradation Technologies

One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of the targeted protein degradation market, over the forecast period. Based on multiple relevant parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period.

The targeted protein degradation market analysis also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as type of degrader (SERD, PROTAC and Molecular Glue), target indication (Breast Cancer and Multiple Myeloma), key geographical regions (North America (US, Canada), Europe (UK, Germany, France, Italy and Spain), Asia-Pacific (China, South Korea, Japan, India and Australia), and Rest of the World (Brazil and Israel)) and sales forecast. In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in the market. In addition, the research report features detailed transcripts of interviews held with the following industry stakeholders (arranged based on the seniority level):

  • Chief Executive Officer and President, Small Company, UK
  • Chief Scientific Officer and Founder, Small Company, UK
  • Former Chief Scientific Officer and Former Vice President, Research, Small Company, US
  • Former Scientific and Business Development Director, Small Company, UK
  • Former Vice President, Business Development and Licensing, and Former Vice President, Biology, Small Company, UK
  • Professor, American University
  • Group Leader, UK-based Research Institute
  • Chief Scientific Officer, Anonymous
  • Director of Oncology Research, Anonymous 

Further, all actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this targeted protein degradation market report are in USD, unless otherwise specified.

Targeted Protein Degradation Market Segmentation Overview

Market Share by Type of Degrader

The global targeted protein degradation market is segmented into SERDs, PROTACs and molecular glues, based on the type of degrader. Owing to the approval of elacestrant (brand name ORSERDU), an orally bioavailable SERD for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer in January 2023, the market segment for SERDs is likely to capture the highest current targeted protein degradation market share (~50%). The trend is unlikely to change in the coming years owing to anticipated approvals of more SERD candidates as compared to other degraders.

Market Share by Target Indication

This section segments the targeted protein degradation market across different target indications, including breast cancer and multiple myeloma. Currently, breast cancer holds the maximum share in the market and this trend is unlikely to change in the future as well. This can be attributed to the rapidly increasing incidence of breast cancer, with over 12.5% of all newly diagnosed cases, making it as one of the most prevalent forms of cancer worldwide.  Further, the market for targeted protein degradation therapies intended for the treatment of multiple myeloma is estimated to grow at an annualized rate (CAGR) of 26% during the forecasted period. It is the second most common hematologic malignancy worldwide, with an estimated annual incidence of 7.1 per 100,000 people.

Market Share by Key Geographical Regions

This segment highlights the distribution of targeted protein degradation market across key geographical regions, including (North America (US, Canada), Europe (UK, Germany, France, Italy and Spain), Asia-Pacific (China, South Korea, Japan, India and Australia), and Rest of the World (Brazil and Israel)).  It is worth highlighting that North America captures close to 83% of the current targeted protein degradation market. Further, the market in Asia-Pacific is expected to grow with a CAGR of more than 60%. This is primarily due to the increasing number of biopharmaceutical start-ups in this region, and likely drug approvals in the region for the treatment of various oncological indications.

Targeted Protein Degradation Market: Key Insights

The Targeted Protein Degradation Market - Industry Trends and Global Forecasts, till 2035: Distribution by Type of Degrader (SERD, PROTAC and Molecular Glue), Target Indication (Breast Cancer and Multiple Myeloma), Key Geographical Regions (North America (US, Canada), Europe (UK, Germany, France, Italy and Spain), Asia-Pacific (China, South Korea, Japan, India and Australia), and Rest of the World (Brazil and Israel)) and Sales Forecast market report features an extensive study of the current market landscape, market size, market share, market analysis, market forecast and future opportunities for the targeted protein degradation companies. The targeted protein degradation market report highlights the efforts of several drug developers engaged in this rapidly emerging market segment of the pharmaceutical industry. Key takeaways of market research report are briefly discussed below.

Competitive Landscape of Targeted Protein Degradation Companies

Currently, over 90 drug developers are involved in the development of targeted protein degradation therapies for various oncological indications, especially breast cancer, solid tumour and prostate cancer. The market landscape features a mix of large, mid-sized and small firms. Additionally, players such as Arvinas, Monte Rosa Therapeutics and Lycia Therapeutics are revolutionizing the targeted protein degradation therapies research and development and driving impactful innovations in the healthcare domain. It is interesting to note that Arvinas is the first company in this domain to develop a PROTAC (Vepdegestrant / ARV-471), first-ever-modality of its class, being investigated in phase III studies. PROTACs hold great potential due to their ability to selectively target proteins, reducing their impact on non-disease-related proteins, offering high specificity. Further, majority of the PROTACs have been designed to be taken orally, easing the administration process for patients.

Competitive Landscape of Targeted Protein Degradation Technology Providers

Presently, around 80 companies are involved in offering various novel and advanced targeted protein degradation technologies. The degraders that are being developed with the help of these technologies include PROTACs, molecular glues, DUB inhibitors, bifunctional degraders, LYTACs, antibody drug conjugate-based degraders and monovalent degraders. It has been observed that the majority of the targeted protein degraders developed using these technologies follow ubiquitin proteasomal pathway. Further, most of the targeted protein degradation technologies are capable of target identification, ligand optimization and ligase selection.

It is worth mentioning that some of the technologies employ advanced tools, such as CADD for designing and analyzing 3D-structure of protein leading to the development of more precise and potent degraders. We believe that targeted protein degradation technologies are poised to play a significant role in shaping the future market landscape, by enabling the development of novel therapeutic modalities for targets that were previously considered undruggable.

Targeted Protein Degradation Market Trends Analysis: Increase in Partnership, Funding, Patents, Publications and Clinical Trials Activity Reflect the Rising Interest in this Industry

Targeted protein degraders ability to degrade the undruggable targets selectively while minimizing off-side toxicity, along with offering broad applicability is anticipated to drive the demand for these therapies for treating oncological and non-oncological disorders over time. In order to cater to this growing demand, several alliances have been forged by various stakeholders in the past few years. These partnerships have enabled the stakeholders to enhance their existing capabilities in terms of drug and technology portfolios to consolidate their presence in the targeted protein degradation industry. In fact, the partnership activity has witnessed a CAGR of ~23%, during the period, 2019-2023. It is worth mentioning that research and development emerged as the most common type of partnership model adopted by the stakeholders in this domain.

In addition, monetary assistance from angel investors, venture capitalists, and funding schemes of various public and private organizations / funds, along with assistance from regulatory authorities, have allowed targeted protein degradation companies to progress their R&D efforts in this domain. It is important to highlight that over USD 13.5 billion has been raised by the companies in this domain, since 2018. For instance, Kymera Therapeutics has raised a total of USD 517 million till date across four rounds of funding. 

It is worth noting that more than 985 patents have been filed / granted related to targeted protein degradation in the last five years. Moreover, over 385 articles related to targeted protein degradation have been published in the last five years. Further, there has been a notable rise in the number of clinical trials in this domain with around 250 clinical trials being registered in the past few years; of these, most of the clinical trials are actively recruiting patients to evaluate targeted protein degradation therapies for breast cancer, B cell lymphoma and others. Driven by the ongoing pace of advancements in this field, growing collaborations, ample financial support from investors, rising number of patents and research articles, and encouraging clinical trial results, the targeted protein degradation market size is likely to witness significant growth during the forecast period.

Regional Analysis: North America Emerged as the Hub of Targeted Protein Degradation Market

Presently, companies based in North America capture half of the targeted protein degradation market share. Driven by the rising interest of stakeholders in the field of targeted protein degradation, the market in North America is anticipated to grow at a CAGR of 25.4%, during the forecast period, 2024-2035. A number of factors contribute to the region’s dominance in this industry which include the presence of several well-established and big pharma companies with diverse experience in research and development of drugs. 

Moreover, the advanced healthcare infrastructure in North America enable drug developers to conduct extensive clinical trials required to meet the stringent regulatory guidelines of the drug approval bodies. However, in terms of market growth, the targeted protein degradation market in Asia-Pacific is likely to grow at a relatively faster pace in the long term, primarily due to likely approval of several degraders and affordable price of treatments in this region.

Targeted Protein Degradation Market Drivers

The rising incidence of cancer has contributed towards development of novel entities for cancer treatment. Owing to this, various researchers and stakeholders are putting in efforts to evaluate different types of modalities. One such modality is targeted protein degraders that has the likely potential to be utilized for treatment of oncological indications. Several ongoing technological advancements in terms of novel PROTAC platforms and molecular glue technologies can pave the way for development of precise and stable degraders. Additionally, the potential of targeted protein degraders in selectively modulating the complex undruggable targets by harnessing cells own machinery, can contribute towards the growth of this market. Furthermore, most of the degraders can be formulated as oral medications, allowing easy administration by patients that can aid in greater adoption of these therapies in the coming years.

Key Targeted Protein Degradation Companies

Examples of the key players involved in the development of targeted protein degraders (the complete list of players is available in the full report) include (in alphabetic order) Arvinas, AstraZeneca, BeiGene, Bristol-Myers Squibb, C4 Therapeutics, Eisai Therapeutics, InnoCare Pharma, Kangpu Biopharmaceuticals, Kintor Pharmaceutical, Loxo Oncology, Medivir, Monte Rosa Therapeutics, Olema Oncology, Radius Health, Ranok Therapeutics, Roche, Sanofi and Zentalis Pharmaceuticals. This global targeted protein degradation market research report includes an easily searchable excel database of all the companies that are developing targeted protein degradation therapies.

Targeted Protein Degradation Market Report Coverage

The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders in this industry, across different geographies. Amongst other elements, the market report includes:

  • A preface providing an introduction to the full report, Targeted Protein Degradation Market (3rd Edition), industry trends and global forecasts till 2035.

Targeted Protein Degradation Market Therapies Targeted Protein Degradation Market Technologies Targeted Protein Degradation Market Distribution by Trial Status
  • An outline of the systematic research methodology adopted to conduct the study on targeted protein degradation, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
  • An overview of economic factors that impact the overall targeted protein degradation market including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
  • An executive summary of the key insights captured during our research, offering a high-level view on the current landscape of targeted protein degradation market and its likely evolution in the short to mid and long term.
  • A general overview of the targeted protein degradation, its evolution, pathway and types of targeted protein degraders. Additionally, the chapter provides information on the therapeutics areas targeted by the targeted protein degraders. It also lays emphasis on the key benefits, key challenges and future perspectives in this domain.
  • A detailed assessment of the current market landscape of targeted protein degradation companies featuring information on stage of development (approved, phase III, phase II, phase I, pre-clinical and discovery), type of degrader (molecular glues, PROTACS, SERDs / SARDs, DUB inhibitors, protein homeostasis modulators and others), biological target (IKZF1, IKZF3, ER+/HER2-, AR, BTK, ER, KRAS, USP7, CRBN and USP30), target enzyme (E3 ubiquitin ligase, CRBN, cullin-ring ligase, lysosomal protease, DUB enzyme and other ligases), target indication and therapeutic area (oncological disorder, neurological disorder, autoimmune disorder, inflammatory disease, immunological disorder and others). Additionally, the chapter includes an overview on the landscape of targeted protein degradation therapy developers, presenting a detailed analysis based on parameters, such as year of establishment, company size (based on employee count), location of headquarters and most active players (in terms of the number of therapies and stage of development).
  • An overview of the current market landscape of targeted protein degradation technologies, based on the type of degrader developed (PROTAC, molecular glue, DUB inhibitor, bifunctional degrader, LYTAC, ADC-based degrader, monovalent degrader and other degraders), protein degradation pathway (proteasomal pathway, lysosomal pathway and other pathways), site of degraded protein (intracellular and extracellular), therapeutic area (oncological disorders, neurological disorders, immunological disorders, autoimmune disorders, infectious diseases, metabolic disorders and other disorders) and discovery step supported (target identification, ligase selection, ligand identification / optimization, PK / PD properties assessment and others), availability of computational modeling ability. In addition, the chapter includes a list of players offering targeted protein degradation technologies, along with information on their year of establishment, company size (in terms of employee count) and location of headquarters.
  • Elaborate profiles of several leading targeted protein degradation companies, featuring information on their year of establishment, location of headquarters, company size (in terms of number of employees), leadership team, financial information (if available), technology portfolio (if available), pipeline overview, recent developments and an informed future outlook.
  • An insightful clinical trial analysis of completed / ongoing clinical trials related to targeted protein degradation, during the time period 2019-2023, based on various relevant parameters, such as trial registration year, number of patients enrolled, trial phase, trial status, patient gender, target indication, study design (type of trial masking, type of intervention model, trial purpose and design allocation), most active sponsor / collaborator (leading industry and non-industry players based on the number of registered trials) and geography.
  • A detailed analysis of grants that have been awarded to various research institutes for targeted protein degradation projects, during the time period 2019-2023, based on the several relevant parameters, such as year of grant award, amount awarded, funding institute centers, support period, type of grant application, purpose of grant award, activity code, study section involved, popular NIH departments (in terms of number of grants), prominent program officers (in terms of number of grants), popular recipient organizations (in terms of number of grants) and distribution of popular recipient organizations by states in the US.  
  • A detailed review of the patents that have been filed / granted for targeted protein degradation, during the time period 2019-2023, based on important parameters such as type of patent, patent application year, patent publication year, patent jurisdiction, Cooperative Patent Classification (CPC) symbols and type of applicant (in terms of number of published patents) and individual patent assignees (in terms of size of intellectual property portfolio). It also features a detailed patent benchmarking analysis and an insightful patent valuation analysis based on parameters, such as type of patent, patent age, patent jurisdiction and number of citations.
  • A detailed publication analysis of peer-reviewed, scientific articles that have been published during the time period 2019-2023, highlighting the research focus within the industry. It also highlights the key trends observed across publications, including information on parameters, such as the year of publication, type of publication, key journal, most active publisher, most active copyright holder, most popular keywords, therapeutic area and key geographical regions.
  • An insightful analysis of the partnerships and collaborations inked in the targeted protein degradation market, during the period 2014-2024, based on several parameters, such as year of partnership, type of partnership, type of partner, type of degrader, most active players (in terms of number of partnerships) and geographical distribution of the partnership activity.
Targeted Protein Degradation Market Year of Partnership Targeted Protein Degradation Market Amount Invested Targeted Protein Degradation Market Growth Scenarios
  • A detailed analysis of the funding and investments made in the targeted protein degradation market, during the period 2018-2024, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in this field, based on several parameters, such as year-wise trend of funding instances, amount invested, type of funding, geographical analysis, leading players (in terms of number of funding instances and amount raised) and investors (in terms of number of funding instances).
  • An in-depth analysis of the factors that can impact the growth of the targeted protein degradation market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities and existing challenges.
  • A detailed market forecast analysis in order to estimate the existing market size and future growth potential of the targeted protein degradation market over the next eleven years Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period till 2035. The report also features the likely distribution of the current and forecasted opportunity within this market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
  • Detailed projections of the current and future targeted protein degradation (TPD) market across type of degrader, such as SERDs, PROTACs and molecular glues.
  • Detailed projections of the current and future targeted protein degradation market across target indication, such as breast cancer and multiple myeloma.
  • Detailed projections of the current and future targeted protein degradation market across key geographical regions, such as (North America (US, Canada), Europe (UK, Germany, France, Italy and Spain), Asia-Pacific (China, South Korea, Japan, India and Australia), and Rest of the World (Brazil and Israel).
  • Detailed projections of the current and future revenues from the sales of approved and phase III drugs developed, including RAD1901 / Elacestrant / Orserdu, Vepdegestrant / ARV-471, Camizestrant / AZD9833, CC-92480 / BMS-986348 / Mezigdomide, LY3484356 / Imlunestrant and OP-1250 / OP-1250-301 / Palazestrant.
  • Detailed market forecast analysis in order to estimate the existing market size and future opportunity for targeted protein degradation technologies over the next eleven years. Based on multiple parameters, likely partnership trends, we have provided an informed estimate on the market evolution during the forecast period till 2035. The report also features the likely distribution of the historical, current and forecasted opportunity within the targeted protein degradation technologies market. 
Targeted Protein Degradation Market Market Movement Analysis Targeted Protein Degradation Market Attractiveness Competitiveness Targeted Protein Degradation Market Deal Financials

Recent Developments in the Targeted Protein Degradation Market

Several recent developments have taken place in the field of targeted protein degradation. We have outlined some of these initiatives below. These developments substantiate the overall market trends that have been outlined in our analysis.

  • In December 2023, C4 Therapeutics entered into a strategic partnership with Merck to develop a portfolio of an emerging modality, Degrader-Antibody Conjugates (DACs) for selectively targeting and neutralizing disease-causing proteins in the cells. 
  • In December 2023, Prelude Therapeutics raised USD 25 million in a private placement round with an aim to fund therapies targeting SMARCA2 gene.
     

Author(s): Ajay Kumar Sharma, Nishta Garg

Frequently Asked Questions

Question 1: What is targeted protein degradation?

Answer: Targeted protein degradation is a novel drug discovery approach that is responsible for destruction of disease-causing proteins by harnessing cells own machinery within the small molecules.

Question 2: What are the types of targeted protein degradation?

Answer: Targeted protein degradation mainly occurs either by proteasomal degradation pathway (a ubiquitin-dependent protein degradation process) or by lysosomal degradation pathway resulting in degradation of cytoplasmic proteins and damaged organelles by auto phagocytosis or endocytosis.

Question 3: How big is the targeted protein degradation market?

Answer: The current global targeted protein degradation market size is around USD 0.48 billion in 2024 and is anticipated to reach close to USD 7 billion by 2035.

Question 4: What is the targeted protein degradation market growth?

Answer: The global targeted protein degradation industry is expected to grow at a CAGR of 32% from 2024 to 2035.

Question 5: Who are the key players in targeted protein degradation industry?

Answer: Examples of the key players involved in the development of targeted protein degraders include Arvinas, AstraZeneca, BeiGene, Bristol-Myers Squibb, C4 Therapeutics, Eisai Therapeutics, InnoCare Pharma, Kangpu Biopharmaceuticals, Kintor Pharmaceutical, Loxo Oncology, Medivir, Monte Rosa Therapeutics, Olema Oncology, Radius Health, Ranok Therapeutics, Roche, Sanofi and Zentalis Pharmaceuticals.

Question 6: What are the factors driving the targeted protein degradation market?

Answer: The growing burden of cancer along with technological advancements driven by the ability of targeted protein degraders to degrade “undruggable” targets are contributing towards the growth of the market.

Question 7: Which segment accounted for the largest targeted protein degradation market share?

Answer: SERDs hold the maximum current market share owing to the approval of Elacestrant (brand name ORSERDU), an orally bioavailable SERD for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer in January 2023.

Question 8: Which region held the highest share in the targeted protein degradation industry?

Answer: North America holds the maximum current market share (~85%) of the targeted protein degradation industry.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com